Dražen Bedeković

Dr. Dražen Bedeković

Department of cardiovascular diseases, University hospital Osijek, Osijek, Osječko-Baranjska Županija, Croatia
orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 August 2023 in Medicina
Verified
Journal Article
Open access
PDF file
Dražen BedekovićDražen Bedeković
Dražen Bedeković
IBIvica Bosnjak
Ivica Bosnjak
SŠSandra Šarić Šarić
Sandra Šarić Šarić
DKDamir Kirner
Damir Kirner
SNSrđan Novak
Srđan Novak
Uncontrolled chronic inflammation results in cardiovascular disease and early death. In this review, we studied the impact of rheumatoid arthritis on the cardiovascular system, including the early and accelerated development of atherosclerosis and its clinical manifestations, focusing on the inflammatory mechanisms leading to arterial wall damage, rapid atherosclerotic plaque formation, and thrombosis. Furthermore, the effect of medications used to treat rheumatoid arthritis on the cardiovascular system was studied. The effect of chronic inflammation and medication on traditional cardiovascular risk factors is not the main subject of this review. We observed that uncontrolled chronic inflammation and some medications directly impact all the stages of atherosclerosis. In conclusion, reducing inflammation and maintaining long-term remission in rheumatoid arthritis may prevent early atherosclerosis. We believe that this review will encourage a better interdisciplinary approach to the management of these patients and further research in this field.

7 August 2023 in Preprints.org
Verified
Preprint
Open access
PDF file
Dražen BedekovićDražen Bedeković
Dražen Bedeković
IBIvica Bosnjak
Ivica Bosnjak
DKDamir Kirner
Damir Kirner
SNSrđan Novak
Srđan Novak
Uncontrolled chronic inflammation results in cardiovascular disease and early death. In this review, we studied the impact of rheumatoid arthritis on the cardiovascular system, including the early and accelerated development of atherosclerosis, and its clinical manifestations, focusing on the inflammatory mechanisms leading to arterial wall damage, rapid atherosclerotic plaque formation, and thrombosis. Furthermore, the influence of medications used to treat rheumatoid arthritis on the cardiovascular system. The influence of chronic inflammation and medicaments on traditional cardiovascular risk factors is not the main subject of this review. We found that uncontrolled chronic inflammation and some medications directly impact all stages of atherosclerosis. In conclusion, reducing inflammation and maintaining long-term remission in rheumatoid arthritis may pre-vent early atherosclerosis. We believe that this review will encourage a better interdisciplinary approach for these patients and further research in this field.

23 May 2023 in BMC Cardiovascular Disorders
Verified
Journal Article
Open access
PDF file
IBIvica Bosnjak
Ivica Bosnjak
Dražen BedekovićDražen Bedeković
Dražen Bedeković
KSKristina Selthofer-Relatić
Kristina Selthofer-Relatić
HRHrvoje Roguljić
Hrvoje Roguljić
IMIvica Mihaljević
Ivica Mihaljević
IBInes Bilić-Čurčić
Ines Bilić-Čurčić
Background: This study aimed to investigate the possible role of serum galectin-3 (Gal-3) levels in the diagnosis and assessment of significant epicardial artery lesions in patients with suspected coronary artery disease (CAD). Methods: This was a single-center cross sectional cohort study including 168 subjects with suspected CAD and indications for coronary angiography divided into three groups: percutaneous coronary intervention (PCI) group (N 64), coronary artery bypass graft surgery (CABG) group (N 57), and group with no coronary stenosis (N 47). Gal-3 levels were measured and the syntax score (Ss) was calculated. Results: The mean value of Gal-3 in the PCI and CABG group was 19.98 ng/ml, while in the control group, it was 9.51 ng/ml (p < 0.001). The highest value of Gal-3 was found in the group of subjects with three-vessel disease (p < 0.001). When subgroups were analyzed by Gal-3 levels (< 17.8 ng/ml low, 18.8–25.9 ng/ml intermediate, > 25 ng/ml high risk) there was a significant difference between at least two Gal-3 groups for the arithmetic mean of Syntax score (p < 0.001). The syntax I’s arithmetic mean at low and intermediate-risk Gal-3 levels was significantly lower than at high-risk Gal-3 levels (p < 0.001). Conclusion: Gal-3 could be used as an additional tool for diagnosis and severity assessment of atherosclerotic disease in patients with suspected CAD. Furthermore, it could help identify high-risk subjects in patients with stable CAD.

18 November 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Dražen BedekovićDražen Bedeković
Dražen Bedeković
DKDamir Kirner
Damir Kirner
IBIvica Bosnjak
Ivica Bosnjak
Aleksandar KibelAleksandar Kibel
Aleksandar Kibel
SŠSandra Šarić Šarić
Sandra Šarić Šarić
VPVišnja Prus
Višnja Prus
Rheumatoid arthritis (RA) increases the risk of cardiovascular mortality and morbidity, including a 50–60% increased risk of cardiovascular disease (CVD). Arterial hypertension (HT) is considered the major contributing risk factor for CVD development in RA patients. In this investigation, we compared the incidence and prevalence of HT between RA and osteoarthritis (OA) and the influence of HT on CVD development in CVD-naive patients in both groups. This was a prospective clinical cohort investigation with an 8-year follow-up period. A total of 201 participants, 124 with RA (investigation group) and 77 with OA (control group), without diagnosed CVD or symptomatic heart failure were included. After selection according to inclusion and exclusion criteria, both groups underwent initial and final visits, and the investigation group underwent annual visits to assess disease activity. Case report forms were completed for each visit. The obtained data were analyzed by a statistician. No difference in the incidence or prevalence of HT was found between the investigation and control groups. No difference in the prevalence of HT was reported between the study groups and age-standardized data from the general population. The investigation group had a higher incidence of CVD than the control group. RA participants with long-term remission had a marginally lower HT prevalence. Although previous studies reported a higher HT prevalence in RA than in OA and the general population, our findings did not support this. The RA group had a higher incidence of CVD, but it is possible that optimal disease control with long-term remission could reduce HT incidence and prevalence while also having beneficial effects on other cardiovascular risk factors (CV) and, consequently, CVD occurrence.

1 March 2008
Verified
Journal Article
Closed access
MGMarija Glasnović
Marija Glasnović
IBIvica Bosnjak
Ivica Bosnjak
AVAleksandar Vcev
Aleksandar Vcev
ISIvan Soldo
Ivan Soldo
EHElizabeta Horvatić
Elizabeta Horvatić
ASAnamarija Soldo
Anamarija Soldo

1 January 2009
Verified
Journal Article
Closed access
MGMarija Glasnović
Marija Glasnović
Dražen BedekovićDražen Bedeković
Dražen Bedeković
IBIvica Bosnjak
Ivica Bosnjak
AVAleksandar Vcev
Aleksandar Vcev
MJMarija Jelić
Marija Jelić